Eli Lilly and Company
LLY · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | $10,590 | $5,240 | $6,245 | $5,582 |
| Dep. & Amort. | $1,767 | $1,527 | $1,523 | $1,548 |
| Deferred Tax | -$2,683 | -$2,341 | -$2,185 | -$802 |
| Stock-Based Comp. | $646 | $629 | $371 | $343 |
| Change in WC | -$5,385 | -$3,055 | -$1 | -$1,013 |
| Other Non-Cash | $3,884 | $2,240 | $1,633 | $1,709 |
| Operating Cash Flow | $8,818 | $4,240 | $7,586 | $7,366 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$5,058 | -$3,448 | -$1,854 | -$1,310 |
| Net Acquisitions | -$948 | -$1,044 | -$327 | -$747 |
| Inv. Purchases | -$776 | -$829 | -$708 | -$1,013 |
| Inv. Sales/Matur. | $523 | $700 | $464 | $847 |
| Other Inv. Act. | -$3,043 | -$2,532 | -$1,337 | -$644 |
| Investing Cash Flow | -$9,302 | -$7,153 | -$3,763 | -$2,868 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $8,901 | $8,650 | -$62 | $501 |
| Stock Issued | $0 | $0 | $0 | $0 |
| Stock Repurch. | -$2,500 | -$750 | -$1,500 | -$1,250 |
| Dividends Paid | -$4,680 | -$4,069 | -$3,536 | -$3,087 |
| Other Fin. Act. | -$491 | -$335 | -$309 | -$296 |
| Financing Cash Flow | $1,230 | $3,496 | -$5,407 | -$4,131 |
| Forex Effect | -$297 | $169 | -$168 | -$206 |
| Net Chg. in Cash | $450 | $752 | -$1,752 | $161 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $2,819 | $2,067 | $3,819 | $3,657 |
| End Cash | $3,268 | $2,819 | $2,067 | $3,819 |
| Free Cash Flow | $414 | -$3,152 | $4,600 | $5,388 |